Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03952325
Title Tesetaxel Plus 3 Different PD-(L)1 Inhibitors in Patients With Metastatic TNBC and Tesetaxel Monotherapy in Patients With HER2 Negative MBC (CONTESSA TRIO)
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Odonate Therapeutics, Inc.
Indications

triple-receptor negative breast cancer

Her2-receptor negative breast cancer

Therapies

Pembrolizumab + Tesetaxel

Nivolumab + Tesetaxel

Tesetaxel

Atezolizumab + Tesetaxel

Age Groups: adult | senior
Covered Countries USA


No variant requirements are available.